Skip to main content
. Author manuscript; available in PMC: 2023 Apr 5.
Published in final edited form as: Cancer Discov. 2022 Oct 5;12(10):2392–2413. doi: 10.1158/2159-8290.CD-21-1146

Figure 5. MHC IIhigh monocytic signature correlates with poor prognosis in AML patients.

Figure 5.

A, Survival plots of TET2 mutated AML patients stratified MHC IIhigh monocytic signature.

B, Survival plots of AML patients stratified by MHC IIhigh monocytic signature.

C, Flow Cytometry representative plots of HLA-DR+ monocytes found in AML patient samples. Monocytes were gated based on their CD64high and CD4intermediate expression levels.

D, Quantification of Monocyte HLA-DR+ cells from NPM1 mutant (n=11) and TET2HR mutant human samples (n=13).